

## News Release

Your Contact

karen.tiano@milliporesigma.com

Phone: +1 978 495 0093

April 30, 2020

## MilliporeSigma Accelerates Readiness of Bioprocessing Facility of the Future

- **Bio4C™ Software Suite, a first-of-its-kind digital ecosystem, combines process control, analytics and plant-level automation**
- **New data visualization and analysis software enables real-time manufacturing intelligence**
- **Saves biopharma manufacturers time and money**

Burlington, Massachusetts, April 30, 2020 – [MilliporeSigma](#) today unveiled the next component of its [BioContinuum™ Platform](#), the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. This transformative software suite will allow users to look across the entire manufacturing process versus individual operational units, giving biomanufacturers complete process control and deep insights, bringing Bioprocessing 4.0 to the here and now.

“The future of bioprocessing is holistic,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “With the launch of our Bio4C™ Software Suite, MilliporeSigma is the first supplier to converge advanced process technologies with software, automation and analytics into one ecosystem, bringing us another step closer to making the digitally enabled facility of the future a reality.”

Biopharmaceutical companies today are under immense pressure to get products to market faster, with every day of delay costing millions in lost revenue. An emerging solution is the integration of software, automation and analytics into biomanufacturing facilities' operations to intensify biologic production, with a vision toward connected and continuous processing. The biopharmaceutical industry is on





## News Release

a journey to evolve and digitize the next generation of bioprocessing to increase speed and lower costs. Bioprocessing 4.0 signifies this new approach to manufacturing. MilliporeSigma has been a key driver of this evolution through its [BioContinuum™ Platform](#).

MilliporeSigma's Bio4C™ Suite was designed based on the company's "4C strategy": – control, connect, collect and collaborate. Control is the basis of everything MilliporeSigma does to run all of its systems. Connect refers to making digital connections between different process steps and giving that visibility to the entire process. Collect is the ability to gather all data into one place and maintain and validate the integrity of that data. Collaborate is how MilliporeSigma will deliver these technologies to its customers in real-time.

Bio4C™ ProcessPad, part of the "Collect" dimension of the Bio4C™ Suite, is a browser-based platform that allows users to acquire, aggregate and analyze data from disparate sources such as equipment, batch records, databases and historians across the bioprocess. MilliporeSigma's Bio4C™ ProcessPad automates the data acquisition and analysis tasks, freeing scientists and engineers to minimize the time to decision and action.

MilliporeSigma will roll out further Bio4C™ Software Suite products and modules throughout 2020 and into the future.

Follow MilliporeSigma on [Twitter](#) @MilliporeSigma, on [Facebook](#) @MilliporeSigma and on [LinkedIn](#).

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to [www.emdgroup.com/subscribe](http://www.emdgroup.com/subscribe) to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

### **About the Life Science business of Merck KGaA, Darmstadt, Germany**

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its \$17 billion acquisition of [Sigma-Aldrich](#) in November 2015, creating a leader in the \$125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live.



## News Release

From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit [www.emdgroup.com](http://www.emdgroup.com).